Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096483 | 1.00 | NEK7 (0.66) | NEK7FLT3 | |
| SCHEMBL25818085 | 0.89 | FLT3 (0.53) | NEK7FLT3 | |
| SCHEMBL30320596 | 0.86 | NEK7 (0.65) | NEK7FLT3 | |
| SCHEMBL24096531 | 0.86 | NEK7 (0.65) | NEK7FLT3 | |
| SCHEMBL30320636 | 0.83 | NEK7 (0.75) | NEK7 | |
| SCHEMBL24096497 | 0.83 | NEK7 (0.75) | NEK7 | |
| SCHEMBL24096525 | 0.82 | NEK7 (0.66) | NEK7FLT3 | |
| SCHEMBL30320515 | 0.82 | NEK7 (0.66) | NEK7FLT3 | |
| SCHEMBL24096573 | 0.81 | NEK7 (0.69) | NEK7FLT3 | |
| SCHEMBL30320545 | 0.81 | NEK7 (0.69) | NEK7FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | NEK7 1/4885FLT3 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.